[1]
El-Shaboury, S.R.; El-Gizawy, S.M.; Atia, N.N.; Abo-Zeid, M.N. Validated spectrodensitometric method for simultaneous estimation of sofosbuvir, ribavirin and saxagliptin in their pure and pharmaceutical dosage forms. Curr. Pharm. Anal., 2018, 14, 212-218.
[2]
Bajerski, L.; Maciel, T.R.; Haas, S.E. Simultaneous determination of curcumin and quinine co-encapsulated in nanoemulsion by stability-indicating lc method. Curr. Pharm. Anal., 2018, 14, 255-261.
[3]
Ahmed, S.; Khan, A.; Sheraz, M.A.; Bano, R.; Ahmad, I. Development and validation of a stability-indicating hplc method for the assay of carvedilol in pure and tablet dosage forms. Curr. Pharm. Anal., 2018, 14, 139-152.
[4]
Joshi, S.A.; Jalalpure, S.S.; Kempwade, A.A.; Peram, M.R. Development and validation of HPLC method to determine colchicine in pharmaceutical formulations and its application for analysis of solid lipid nanoparticles. Curr. Pharm. Anal., 2018, 14, 76-83.
[5]
Wang, W.; Vellaisamy, K.; Li, G.; Wu, C.; Ko, C.N.; Leung, C.H.; Ma, D.L. Development of a long-lived luminescence probe for visualizing β-Galactosidase in ovarian carcinoma cells. Anal. Chem., 2017, 89, 11679-11684.
[6]
Lin, S.; Lu, L.; Kang, T.S.; Mergny, J.L.; Leung, C.H.; Ma, D.L. Interaction of an Iridium(III) Complex with G-Quadruplex DNA and its application in luminescent switch-on detection of siglec-5. Anal. Chem., 2016, 88, 10290-10295.
[7]
Liu, C.; Yang, C.; Lu, L.; Wang, W.; Tan, W.; Leung, C.H.; Ma, D.L. Luminescent iridium(III) complexes as COX-2-specific imaging agents in cancer cells. Chem. Commun., 2017, 53, 2822-2825.
[8]
Wang, M.; Mao, Z.; Kang, T.S.; Wong, C.Y.; Mergny, J.L.; Leung, C.H.; Ma, D.L. Conjugating a groove-binding motif to an Ir(III) complex for the enhancement of G-quadruplex probe behavior. Chem. Sci., 2016, 7, 2516-2523.
[9]
Hori, Y.; Otomura, N.; Nishida, A.; Nishiura, M.; Umeno, M.; Suetake, I.; Kikuchi, K. Synthetic-molecule/protein hybrid probe with fluorogenic switch for live-cell imaging of dna methylation. J. Am. Chem. Soc., 2018, 140, 1686-1690.
[10]
Rodriguez, J.; Castaneda, G.; Lizcano, I.; Villa, J.C. A rapid, direct and validated hplc- fluorescence method for the quantification of abiraterone and abiraterone acetate in urine and serum samples from patients with castration- resistant prostate cancer. Curr. Pharm. Anal., 2018, 14, 233-238.
[11]
Hu, Y.; Feng, J.; Liang, G. Vinoprabath.; Fu, L.; Pan, J.; Zhang, X.; Xiang, Z. A rapid and simple UPLC method for the quantitative determination of compound X22 in rat plasma and its application to a pharmacokinetic study. Curr. Pharm. Anal., 2018, 14, 116-120.
[12]
Shah, A.; Kothari, C.; Patel, N. Concurrent estimation of gabapentin and nortriptyline hydrochloride in their combined dosage form using OPA-β-Mercaptoethanol derivatization by spectrophotometric and spectrofluorimetric methods. Curr. Pharm. Anal., 2017, 13, 241-249.
[13]
Jalalizadeh, H.; Souri, E.; Tehrani, M.B.; Jahangiri, A. Validated HPLC method for the determination of gabapentin in human plasma using pre-column derivatization with 1-fluoro-2,4-dinitrobenzene and its application to a pharmacokinetic study. J. Chromatogr. B , 2007, 854, 43-47.
[14]
Gupta, A.; Ciavarella, A.B.; Sayeed, V.A.; Khan, M.A.; Faustin, P.J. Development and application of a validated HPLC method for the analysis of dissolution samples of gabapentin drug products. J. Pharm. Biomed. Anal., 2008, 46, 181-186.
[15]
Bartoszyk, G.D.; Meyerson, N.; Reimann, W.; Satzinger, G.; von-Hodenberg, A. “Gabapentin,” in New Anticonvulsant Drugs. B S
Meldrum and B. J. Porter, Eds. 1986 pp. 147-163, John Libbey London, UK
[16]
Tallian, K.B.; Nahata, M.C.; Lo, W.; Tsao, C.Y. Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. J. Clin. Pharm. Ther., 2004, 29, 511-515.
[17]
Ouellet, D.; Bockbrader, H.N.; Wesche, D.L.; Shapiro, D.Y.; Garofalo, E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res., 2001, 47, 229-241.
[18]
Taylor, C.P.; Angelotti, T.; Fauman, E. Pharmacology and mechanism of action of pregabalin: The calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res., 2007, 73, 137-150.
[19]
Ramsey, R.E. Clinical efficacy and safety of gabapentin. Neurology, 1994, 44(suppl 5), 523-530.
[20]
Sivenius, J.; Kalvianinen, R.; Ylinin, A.; Riekkinin, P. Double blind study of gabapentin in the treatment of partial seizures. Epilepsia, 1991, 32, 539-542.
[21]
Johannessen, S.I.; Tomson, T. Pharmacokinetics variability of newer antiepileptic drugs: When is monitoring needed? Clin. Pharmacokinet., 2006, 45, 1061-1075.
[22]
Krasowski, M.D. Therapeutic drug monitoring of the newer antiepilepsy medications. Pharmaceuticals, 2010, 3, 1909-1935.
[23]
Dahl, J.B.; Mathiesen, O.; Møiniche, S. Protective premedication’: An option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain. Acta Anaesthesiol. Scand., 2004, 48, 1130-1136.
[24]
Markman, J.D.; Dworkin, R.H. Ion channel targets and treatment efficacy in neuropathic pain. J. Pain, 2006, 7(1 Suppl 1), S38-S47.
[25]
Nair, A.B.; Kumria, R.; Al-Dhubiab, B.E. Noninvasive sampling of gabapentin by reverse iontophoresis. Pharm. Res., 2015, 32, 1417-1424.
[26]
Berry, D.J.; Beran, R.G.; Plunkeft, M.J.; Clarke, L.A.; Hung, W.T. The absorption of gabapentin following high dose escalation. Seizure, 2003, 12, 28-36.
[27]
Giri, T.K.; Chakrabarty, S.; Ghosh, B. Transdermal reverse iontophoresis: A novel technique for therapeutic drug monitoring. J. Controlled. Release, 2017, 246, 30-38.
[28]
Leboulanger, B.; Guy, R.H.; Delgado-Charro, M.B. Non invasive monitoring of phenytoin by reverse iontophoresis. Eur. J. Pharm. Sci., 2004, 22, 427-433.
[29]
Tamada, J.A.; Garg, S.; Jovanovic, L.; Pitzer, K.R.; Fermi, S.; Potts, R.O. Noninvasive glucose monitoring: comprehensive clinical results. J Am. Med. Assoc, 1999, 282, 1839-1844.
[30]
Pitzer, K.R.; Desai, S.; Dunn, T.; Edelman, S.; Jayalakshmi, Y.; Kennedy, J.; Tamada, J.A.; Potts, R.O. Detection of hypo- glycemia with the GlucoWatch biographer. Diabetes Care, 2001, 24, 881-885.
[31]
Degim, I.T.; Ilbasmis, S.; Dundaroz, R.; Oguz, Y. Reverse iontophoresis: A non-invasive technique for measuring blood urea level. Pediatr. Nephrol., 2003, 18, 1032-1037.
[32]
Merino, V.; Lopez, A.; Hochstrasser, D.; Guy, R.H. Noninvasive sampling of phenylalanine by reverse iontophoresis. J. Control. Release, 1999, 61, 65-69.
[33]
Mize, N.K.; Buttery, M.; Daddona, P.; Morales, C.; Cormier, M. Reverse iontophoresis: monitoring prostaglandin E2 associated with cutaneous inflammation in vivo. Exp. Dermatol., 1997, 6, 298-302.
[34]
Nixon, S.; Sieg, A.; Delgado-Charro, M.B.; Guy, R.H. Reverse iontophoresis of Llactate: In vitro and in vivo studies. J. Pharm. Sci., 2007, 96, 3457-3465.
[35]
Delgado-Charro, M.B.; Guy, R.H. Transdermal reverse iontophoresis of valproate: a non-invasive method for therapeutic drug monitoring. Pharm. Res., 2003, 20, 1508-1513.
[36]
Leboulanger, B.; Guy, R.H.; Delgado-Charro, M.B. Non-invasive lithium monitoring by reverse iontophoresis. an in vivo study. Clin. Chem., 2004, 50, 2091-2100.
[37]
Santi, P.; Guy, R.H. Reverse iontophoresis - Parameters determining electroosmotic flow: I. pH and ionic strength. J. Controlled. Release, 1996, 38, 159-165.
[38]
Fluhr, J.W.; Elias, P.M. Stratum corneum pH: Formation and function of the acid mantle. Exog. Dermatol., 2002, 1, 163-175.
[39]
Martin, A. Physical Pharmacy, 4th ed; Williams and Wilkins: Baltimore, USA, 1993, pp. 169-190.
[40]
Sekkat, N.; Naik, A.; Kalia, Y.N.; Glikfeld, P.; Guy, R.H. Reverse iontophoretic monitoring in premature neonates: feasibility and potential. J. Controlled. Release, 2002, 81, 83-89.
[41]
Nojavan, S.; Pourahadi, A.; Davarani, S.S.H.; Morteza-Najarian, A.; Abbassi, M.B. Electromembrane extraction of zwitterionic compounds as acid or base: Comparison of extraction behavior at acidic and basic pHs. Analytica. Chimica. Acta, 2012, 745, 45-52.
[42]
Smith, K.A.; Hao, J.; Li, S.K. Effects of ionic strength on passive and iontophoretic transport of cationic permeant across human nail. Pharm. Res., 2009, 26, 1446-1455.
[43]
Ho, H.; Huang, F.; Soroloski, T.D.; Sheu, M. The influence of cosolvents on the in vitro percutaneous penetration of diclofenac sodium from a gel system. J. Pharm. Pharmacol., 1994, 46, 636-642.
